Physician profile
Howard Goldschmidt
NPI 1619940038
$7,446.05
in general payments reported to CMS, 2019-2025
28 companies · $1,928 in 2025
The $1,928 reported for 2025 was more than what 83% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,000 · 2020: $417 · 2021: $764 · 2022: $1,068 · 2023: $342 · 2024: $1,928 · 2025: $1,928.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,250 · Food and Beverage: $1,865 · Education: $82.99.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,250.08 |
| Food and Beverage | $1,864.67 |
| Education | $82.99 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Edwards Lifesciences Corporation | $1,779.83 | 2023-2025 | Evoque, Pascal |
| Abbott Laboratories | $1,508.73 | 2022-2024 | Cardiomems, Mitraclip |
| Pfizer INC. | $442.76 | 2019-2024 | |
| Novartis Pharmaceuticals Corporation | $362.27 | 2019-2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $355.67 | 2019-2025 | Jardiance |
| Janssen Pharmaceuticals, INC | $304.56 | 2019-2024 | Xarelto |
| Sanofi-Aventis U.S. LLC | $277.75 | 2019-2023 | |
| Boston Scientific Corporation | $262.68 | 2019-2024 | Watchman Flx, Watchman Access System, Watchman |
| Amgen INC. | $253.37 | 2019-2024 | Repatha |
| E.R. Squibb & Sons, L.L.C. | $208.89 | 2019-2025 | Eliquis, Camzyos |
| Astrazeneca Pharmaceuticals LP | $204.93 | 2019-2024 | |
| Vifor Pharma, INC. | $200.00 | 2021 | |
| Arbor Pharmaceuticals, INC. | $170.35 | 2019-2021 | |
| Regeneron Healthcare Solutions, INC. | $163.14 | 2019-2022 | |
| Novo Nordisk INC | $158.58 | 2021-2025 | Wegovy, Ozempic, Rybelsus |
Show all 28 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Kowa Pharmaceuticals America, INC. | $150.87 | 2019-2023 | Livalo |
| Medtronic, INC. | $149.45 | 2022 | |
| Amarin Pharma, INC. | $116.87 | 2019-2023 | |
| Cvrx, INC. | $97.47 | 2022-2024 | Barostim Neo System |
| Merck Sharp & Dohme LLC | $67.74 | 2021-2024 | Verquvo |
| Abiomed | $41.28 | 2025 | |
| Heartflow, INC. | $37.00 | 2023-2025 | Ffrct |
| Esperion Therapeutics, INC. | $27.59 | 2021-2022 | |
| Kiniksa Pharmaceuticals, LTD. | $27.46 | 2022 | |
| Preventice Services, LLC | $25.00 | 2019 | |
| Irhythm Technologies, INC. | $23.57 | 2019 | |
| Azurity Pharmaceuticals, INC. | $14.55 | 2022 | |
| Gilead Sciences, INC. | $13.69 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Howard Goldschmidt listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.